Prime Medicine Announces Proposed Public Offering of Common Stock

Core Viewpoint - Prime Medicine, Inc. has initiated an underwritten public offering of its common stock, with plans to grant underwriters a 30-day option to purchase an additional 15% of the shares offered [1] Company Overview - Prime Medicine is a biotechnology company focused on developing a new class of one-time curative genetic therapies using its proprietary Prime Editing platform, which aims to provide precise and efficient gene editing [6] - The company is advancing a diversified portfolio of investigational therapeutic programs in core areas such as liver, lung, immunology, and oncology, targeting diseases with well-understood biology and clear clinical development paths [7] Offering Details - The shares are being offered under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC) on November 3, 2023, and declared effective on November 13, 2023 [3] - The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC [5]